# Tesaro, Inc. clinical trials: 33 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials with Tesaro, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tesaro, Inc.: 33 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/tesaro-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 9, 2025 | NCT06964165 | A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous... | Tesaro, Inc. | Phase 2 | Terminated | Ovarian Neoplasms | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06964165) |
| March 2, 2023 | NCT05751629 | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | Tesaro, Inc. | Phase 2 | Completed | Ovarian Neoplasm | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05751629) |
| June 11, 2019 | NCT03981796 | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or... | Tesaro, Inc. | Phase 3 | Active not recruiting | Neoplasms | 785 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03981796) |
| May 20, 2019 | NCT03955471 | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant... | Tesaro, Inc. | Phase 2 | Terminated | Ovarian Neoplasms | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03955471) |
| July 27, 2018 | NCT03602859 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line... | Tesaro, Inc. | Phase 3 | Active not recruiting | Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03602859) |
| July 2, 2018 | NCT03574779 | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer | Tesaro, Inc. | Phase 2 | Completed | Ovarian Neoplasms | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03574779) |
| December 2, 2017 | NCT03359850 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | Tesaro, Inc. | Phase 1 | Completed | Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03359850) |
| November 6, 2017 | NCT03329937 | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer | Tesaro, Inc. | Phase 1 | Completed | Neoplasms, Breast | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03329937) |
| November 1, 2017 | NCT03329001 | Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule | Tesaro, Inc. | Phase 1 | Completed | Neoplasms | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03329001) |
| October 31, 2017 | NCT03326193 | A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on... | Tesaro, Inc. | Phase 2 | Completed | Ovarian Neoplasms | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03326193) |
| October 13, 2017 | NCT03308942 | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | Tesaro, Inc. | Phase 2 | Completed | Neoplasms | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03308942) |
| October 12, 2017 | NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | Tesaro, Inc. | Phase 1 | Completed | Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03307785) |
| August 16, 2017 | NCT03250832 | Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors | Tesaro, Inc. | Phase 1 | Completed | Neoplasms | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03250832) |
| January 20, 2017 | NCT03025867 | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | Tesaro, Inc. | Not applicable | Approved for marketing | Recurrent Ovarian Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03025867) |
| June 29, 2016 | NCT02817633 | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Tesaro, Inc. | Phase 1 | Active not recruiting | Neoplasms | 463 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02817633) |
| March 22, 2016 | NCT02715284 | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | Tesaro, Inc. | Phase 1 | Active not recruiting | Neoplasms | 729 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02715284) |
| January 18, 2016 | NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | Tesaro, Inc. | Phase 1/2 | Completed | Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast... | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02657889) |
| January 13, 2016 | NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line... | Tesaro, Inc. | Phase 3 | Active not recruiting | Ovarian Neoplasms | 733 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02655016) |
| June 19, 2015 | NCT02476552 | Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer | Tesaro, Inc. | Phase 1 | Completed | Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02476552) |
| May 5, 2015 | NCT02434861 | An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin... | Tesaro, Inc. | Phase 1 | Completed | Chemotherapy-induced Nausea and Vomiting | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02434861) |
| March 9, 2015 | NCT02382666 | A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy... | Tesaro, Inc. | Phase 1 | Completed | Chemotherapy-induced Nausea and Vomiting | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02382666) |
| February 3, 2015 | NCT02354586 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | Tesaro, Inc. | Phase 2 | Completed | Ovarian Neoplasms, Ovarian Cancer | 463 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02354586) |
| November 7, 2014 | NCT02285647 | An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant | Tesaro, Inc. | Phase 1 | Completed | Chemotherapy-induced Nausea and Vomiting | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02285647) |
| January 29, 2014 | NCT02048488 | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | Tesaro, Inc. | Phase 1/2 | Completed | Solid Tumors, Lymphomas | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02048488) |
| July 23, 2013 | NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | Tesaro, Inc. | Phase 3 | Terminated | Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene... | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01905592) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 2 |
| Phase 2 | 8 |
| Phase 3 | 8 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Active not recruiting | 5 |
| Terminated | 5 |
| Approved for marketing | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Ovarian Neoplasms | 16 |
| Neoplasms | 12 |
| Vomiting | 6 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Nausea | 3 |
| Breast Neoplasms | 3 |
| Colorectal Neoplasms | 2 |
| Lymphoma | 2 |
| Melanoma | 1 |
| Neoplasm Metastasis | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Leukemia, Prolymphocytic, T-Cell | 1 |
| Prostatic Neoplasms | 1 |
| Endocrine Gland Neoplasms | 1 |
| Ovarian Diseases | 1 |
| Adnexal Diseases | 1 |
| Genital Diseases, Female | 1 |
| Genital Diseases, Male | 1 |
| Genital Neoplasms, Female | 1 |
| Urogenital Neoplasms | 1 |
| Endocrine System Diseases | 1 |
| Gonadal Disorders | 1 |
| Genital Neoplasms, Male | 1 |
| Prostatic Diseases | 1 |
| Triple Negative Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
- [Grout companies in the United States](https://specstream.ai/data/businesses/grout-companies/united-states)
- [Coworking spaces in the United States](https://specstream.ai/data/businesses/coworking-spaces/united-states)
- [B2B equipment maintenance and repair companies in the United States](https://specstream.ai/data/businesses/b2b-equipment-maintenance-and-repair-companies/united-states)
- [Tenant and eviction law firms in the United States](https://specstream.ai/data/businesses/tenant-and-eviction-law-firms/united-states)
